dc.contributor.author | Bughda, R | |
dc.contributor.author | Dimou, P | |
dc.contributor.author | D'Souza, RR | |
dc.contributor.author | Klampatsa, A | |
dc.coverage.spatial | New Zealand | |
dc.date.accessioned | 2024-05-20T08:46:35Z | |
dc.date.available | 2024-05-20T08:46:35Z | |
dc.date.issued | 2021-01-01 | |
dc.identifier | 291767 | |
dc.identifier.citation | ImmunoTargets and Therapy, 2021, 10 pp. 313 - 323 | |
dc.identifier.issn | 2253-1556 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6224 | |
dc.identifier.eissn | 2253-1556 | |
dc.identifier.eissn | 2253-1556 | |
dc.identifier.doi | 10.2147/ITT.S291767 | |
dc.identifier.doi | 10.2147/ITT.S291767 | |
dc.description.abstract | Fibroblast activation protein (FAP) is a membrane protease that is highly expressed by cancer-associated fibroblasts (CAFs). FAP can modulate the tumor microenvironment (TME) by remodeling the extracellular matrix (ECM), and its overexpression on CAFs is associated with poor prognosis in various cancers. The TME is in part accountable for the limited efficacy of chimeric antigen receptor (CAR)-T cell therapy in treatment of solid tumors. Targeting FAP with CAR-T cells is one of the strategies being researched to overcome the challenges in the TME. This review describes the role of FAP in the TME and its potential as a target in CAR-T cell immunotherapy, summarizes the preclinical studies and clinical trials of anti-FAP-CAR-T cells to date, and reviews possible optimizations to augment their cytotoxic efficiency in solid tumors. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 313 - 323 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | DOVE MEDICAL PRESS LTD | |
dc.relation.ispartof | ImmunoTargets and Therapy | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | CAR T-cells | |
dc.subject | fibroblast-activating-protein | |
dc.subject | fibroblasts | |
dc.subject | immunotherapy | |
dc.subject | solid tumors | |
dc.subject | stroma | |
dc.subject | tumor microenvironment | |
dc.title | Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-07-20 | |
dc.date.updated | 2024-05-14T12:29:14Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.2147/ITT.S291767 | |
rioxxterms.licenseref.startdate | 2021-01-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/34386436 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Thoracic Oncology Immunotherapy Group (TOIG) | |
pubs.organisational-group | ICR/Students | |
pubs.organisational-group | ICR/Students/PhD and MPhil | |
pubs.organisational-group | ICR/Students/PhD and MPhil/20/21 Starting Cohort | |
pubs.organisational-group | ICR/ImmNet | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.2147/itt.s291767 | |
pubs.volume | 10 | |
icr.researchteam | Thor Onco Immuno Group | |
dc.contributor.icrauthor | Bughda, Reyisa | |
dc.contributor.icrauthor | Klampatsa, Astero | |
icr.provenance | Deposited by Dr Astero Klampatsa on 2024-05-14. Deposit type is initial. No. of files: 1. Files: Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells Launching an Attack on Tumor Stroma.pdf | |